Effectiveness of Tezepelumab on Asthma control and Cough: A prospective, multi-center, observational study (Tezepelumab PRO study)

AstraZeneca K.K.0 sites90 target enrollmentStarted: September 27, 2023Last updated: May 8, 2025

Overview

No summary available.

•Patients aged >=18 years who provide informed consent and who receive new prescription of Tezepelumab as per the physician's decision at baseline according to the package insert saying "Tezepelumab is given to patient with asthma (limited to severe or refractory patient whose asthma symptoms cannot be controlled even with existing treatment)"
•ACQ-6 >=1.5 at baseline
•Patients with persistent cough >=8 weeks up until the baseline visit according to The Japanese Respiratory Society Guidelines for the Management of Cough and Sputum 2019

•Patients who had asthma exacerbation within one month before study enrollment
•Patients who had the biologics treatment in following period prior to the enrollment
•omalizumab in 2 or 4 weeks depending on the body weight and total IgE amount
•mepolizumab in 4 weeks
•Benralizumab in 8 weeks
•Dupilumab in 2 weeks
•Patients with cough related diseases other than asthma as determined by treating physicians
•Patients participating in studies that affect this study (study with other interventional treatment to evaluate efficacy/safety of treatment in patients with cough, asthma, or allergic/eosinophilic diseases)
•Any disorder, including heart failure, malignancy, morbid obesity(BMI>=35) , respiratory infectious disease that is not stable (e.g. patients who need medical treatment) in the opinion of the investigator and could:
•Affect the safety of the patient throughout the study

Mean change in ACQ-6 at week 52 from baseline

No secondary outcomes reported

Sponsor